The first-of-its-kind TEAM-HF study seeks to improve clinical outcomes in patients with worsening heart failure Trial establishes new, objective criteria to identify patients most at risk for developing end-stage heart failure and potentially offer life-saving therapeutic options sooner…
Tag: Abbott
Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping
Enrollment completed ahead of schedule in the global IDE for Abbott’s Volt™ PFA System Global FOCALFLEX trial now underway for Abbott’s TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™, receives U.S. Food and Drug Administration…
MemorialCare Heart & Vascular Institute at Long Beach Medical Center is First Hospital in Southern California to Perform Transcatheter Aortic Valve Implantation with Navitor Titon 35mm Valve
This is the first 35mm size valve implantation giving those with large native aortic valves at high-risk a minimally invasive option – avoiding open heart surgeryLONG BEACH, Calif., June 21, 2024 /PRNewswire/ — Yesterday, MemorialCare Heart & Vascular Institute at Long Beach Medical Center was the first hospital in Southern California to implant a 35mm Abbott Titan Navitor Valve during a Transcatheter Aortic Valve Implantation (TAVI) procedure. The TAVI procedure is crucial for patients who have severe aortic stenosis and are at extreme risk for open-heart surgery. This offers a minimally invasive approach which shortens hospital stays, reduces risk of infection and lessens recovery time.
Continue Reading
Titan Navitor Valve Team from MemorialCare Heart and Vascular Institute at Long Beach Medical Center
“We are very proud of Dr. Anthony Chyou and Dr. Ali Khoynezhad for leading us through this transformational time of our heart and vascular institute,” says David Shavelle, M.D., FACC, chief of cardiology, MemorialCare Heart & Vascular Institute; medical director, adult cardiology & interventional lab, MemorialCare Heart & Vascular Institute at Long Beach Medical Center. “We have always taken pride in creating an environment where our patients are given personalized treatment. The Navitor Titan 35mm Valve allowed us to provide a minimally invasive treatment option to a high-risk patient with severe aortic stenosis.”
The Navitor valve is one of the newest heart valve devices approved by the U.S. Food and Drug Administration for TAVI, also known as Transcatheter Aortic Valve Replacement (TAVR). This device is different from other heart valve replacement valves on the market due to improved blood flow (hemodynamic) performance and ease of use.
“The intuitive design of the Navitor TAVI System allows more patients who normally would not be viable candidates for a Transcatheter Aortic Valve Replacement procedure access to a valve replacement,” says Optum partnering physician Anthony Chyou, M.D., who is also an interventional cardiologist at MemorialCare Heart & Vascular Institute at Long Beach Medical Center. “Patients with large native aortic valves and severe aortic stenosis valve disease may not have been able to receive treatment as prior TAVI valves were not large enough to accommodate their anatomy.”Heart valve disease limits the ability of the heart to pump blood through the entire body. The Navitor TAVI System has been tested and shown to greatly improve the blood flow of patients with symptomatic severe aortic stenosis, helping their hearts resume to normal, healthy blood flow performance quickly.”MemorialCare is dedicated to state-of-the-art, patient-centric care to our community, and this ‘first in the region’ procedure is a testament to our continued commitment to excellent patient care,” says Ali Khoynezhad, M.D., director, aortic and arrythmia surgery, MemorialCare Heart & Vascular Institute at Long Beach Medical Center.The Navitor TAVI System has been rigorously tested and proven to yield positive 30-day outcomes in patients with symptomatic severe aortic stenosis, including a 0% chance of moderate or severe paravalvular leak (PVL), 1.9% chance of all-cause mortality, 1.9% chance of disabling stroke, and 4.2% chance of major vascular complications, proving its remarkable safety and effectiveness in TAVR procedures.About MemorialCare Long Beach Medical Center:MemorialCare Long Beach Medical Center is a member of MemorialCare, a not-for-profit, integrated healthcare system. Long Beach Medical Center has been providing the community with compassionate, quality health care for more than 100 years. At the forefront of specialized care, research, and education, Long Beach Medical Center uses the most advanced healthcare technologies, including pioneering surgical systems like – ExactechGPS® and ExcelsiusGPS®. Recognized among the top 3% of all California acute care hospitals, Long Beach Medical Center is recognized as “Best Hospital” for OBGYN and Orthopedics and ranked regionally in the Los Angeles Metro Area by U.S. News & World Report and earned Magnet® recognition for nursing excellence. With premier centers dedicated to cancer, heart, rehabilitation, orthopedics, neurosciences, and trauma, physicians and surrounding hospitals continually refer to its accredited programs. For more information, visit memorialcare.org/LongBeach.SOURCE MemorialCare Long Beach Medical Center
ABBOTT ANNOUNCES FIRST GLOBAL PROCEDURES IN A CLINICAL TRIAL OF ITS VOLT™ PULSED FIELD ABLATION SYSTEM TO TREAT PATIENTS WITH ABNORMAL HEART RHYTHMS
ABBOTT PARK, Ill., Jan. 18, 2024 /PRNewswire/ — Abbott (NYSE: ABT) today announced the first global procedures have been conducted using the company’s new Volt™ Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrial fibrillation […]
Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States
ST. LOUIS, Oct. 31, 2023 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the United States have been treated successfully utilizing Abbott’s EnSite™ […]
Late-Breaking Data Showcase the Benefits of Abbott’s Minimally Invasive Devices for People With Leaky Heart Valves
New data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2023 from the TRILUMINATE™ pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid regurgitation (a leaky valve) with TriClip™, an investigational device in the U.S….
Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range
ABBOTT PARK, Ill., Oct. 18, 2023 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2023. Third-quarter GAAP diluted EPS of $0.82 and adjusted diluted EPS of $1.14, which excludes specified items. Abbott narrowed its full-year 2023 EPS guidance range. […]
ABBOTT REPORTS SECOND-QUARTER 2023 RESULTS; INCREASES OUTLOOK FOR UNDERLYING BASE BUSINESS
ABBOTT PARK, Ill., July 20, 2023 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2023. Second-quarter GAAP diluted EPS of $0.78 and adjusted diluted EPS of $1.08, which excludes specified items. Projected full-year 2023 diluted EPS on a […]
European Study Finds the Abbott CardioMEMS Sensor Results in Improved Quality of Life and 44% Reduction in Heart Failure Hospitalizations
MONITOR-HF is the third randomized, controlled trial globally to show a significant health benefit for indicated heart failure patients CardioMEMS is a paperclip-sized sensor that can remotely flag to a patient’s clinical team the early warning signs of worsening heart […]
Abbott Unveils Late-Breaking Data Showing the World’s First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints
Abbott’s AVEIR™ DR i2i™ IDE study is the industry’s first prospective study on the safety and performance of the world’s first dual-chamber leadless pacemaker The study successfully met all three of its primary safety and performance endpoints Abbott’s investigational AVEIR […]